NEW YORK (GenomeWeb News) – Cisbio will distribute Multispan's cell line portfolio in the US, under an agreement announced today by the firms.
The deal covers Multispan's cell line platform of more than 320 human and 209 rodent expression-ready cDNAs and 240 stable cell lines. The cell lines express G-protein coupled receptors in their native forms and "enable comprehensive investigation of effects of drug candidates on downstream signaling of each GPCR," the firms said in a joint statement.
Boston-based Cisbio will make the cell lines available to customers alongside its own platform for GPCR screening and cell surface receptor investigation.
According to the partners, the deal offers pharmaceutical and biotechnology researchers a new supply source of cell lines for functional assay development in GPCR drug development.
Further terms of the alliance were not disclosed.